KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Diluted Average) (2016 - 2025)

Sarepta Therapeutics has reported Shares Outstanding (Diluted Average) over the past 9 years, most recently at $100.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 7.19% year-over-year to $100.1 million; the TTM value through Dec 2025 reached $100.1 million, down 7.19%, while the annual FY2025 figure was $100.1 million, 7.19% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $100.1 million at Sarepta Therapeutics, up from $98.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $107.9 million in Q4 2024 and troughed at $88.6 million in Q3 2023.
  • A 3-year average of $98.0 million and a median of $99.1 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 16.75% in 2024 and later decreased 7.19% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $92.4 million in 2023, then increased by 16.75% to $107.9 million in 2024, then dropped by 7.19% to $100.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SRPT at $100.1 million in Q4 2025, $98.5 million in Q3 2025, and $106.6 million in Q2 2025.